GRWD5769 shrank tumours by at least 30% in 15 of 83 patients in a Phase 1 trial The drug inhibits ERAP1 enzyme, making cancer cells visible to immunotherapy Trial included advanced cases of lung, bowel, liver, cervical, bladder, head/neck cancers